| B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | #cases: 12.0 | Year | USG control | Base rate | USG-owned vs. contract | High-cost (approximate guess; 1=yes, 0=no) | ||||||||||||||||||
2 | TOTAL | 2.33 | 19.4% | |||||||||||||||||||||
3 | Automobile | 1886 | 0.00 | private/academia/non-US | 0.0000 | |||||||||||||||||||
4 | Airplane | 1903 | 0.00 | private/academia/non-US | 0.0000 | |||||||||||||||||||
5 | Mass production | 1913 | 0.00 | private/academia/non-US | 1.0000 | |||||||||||||||||||
22 | Viral enhancement (first demonstrated on mousepox) | 2001 | 0.00 | private/academia/non-US | probably low | |||||||||||||||||||
23 | First synthetic virus (poliovirus) | 2002 | 1.00 | contract | probably low | |||||||||||||||||||
24 | Sequencing of the human genome | 2003 | 0.00 | private/academia/non-US | 1.0000 | |||||||||||||||||||
25 | Viral sequencing (first demonstrated on Spanish Influenza) | 2005 | 1.00 | USG-owned | probably low | |||||||||||||||||||
26 | Extending the host range of a virus via rational protein design | 2007 | 0.00 | private/academia/non-US | probably low | |||||||||||||||||||
27 | First synthetic bacterial genome | 2010 | 0.00 | private/academia/non-US | probably low | |||||||||||||||||||
28 | H5N1 viral research (“gain-of-function”) | 2012 | 0.00 | private/academia/non-US | 0.0000 | |||||||||||||||||||
29 | Nanotechnology | ongoing | 0.00 | private/academia/non-US | 1.0000 | |||||||||||||||||||
30 | Synthetic biology | ongoing | 0.33 | contract | probably low |